HUP9801746A2 - Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek - Google Patents

Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek

Info

Publication number
HUP9801746A2
HUP9801746A2 HU9801746A HUP9801746A HUP9801746A2 HU P9801746 A2 HUP9801746 A2 HU P9801746A2 HU 9801746 A HU9801746 A HU 9801746A HU P9801746 A HUP9801746 A HU P9801746A HU P9801746 A2 HUP9801746 A2 HU P9801746A2
Authority
HU
Hungary
Prior art keywords
lymphotoxin
complexes
beta
alfa
receptor antibodies
Prior art date
Application number
HU9801746A
Other languages
English (en)
Inventor
Christopher D. Benjamin
Jeffrey L. Browning
Werner Meier
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP9801746A2 publication Critical patent/HUP9801746A2/hu
Publication of HUP9801746A3 publication Critical patent/HUP9801746A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány tárgyát őlyan limfőtőxin-a/ (LT-a/) heterőmer kőmplexekképezik, amelyek limfőtőxin-receptőrt (LT--R) aktiváló szerekjelenlétében daganatsejtekre citőtőxikűs hatásőkat indűkálnak,valamint őlyan LT--R ellen irányűló antitestek, amelyek önmagűkbanvagy más LT--R aktiváló szerekkel kőmbinálva, LT-a/ a kőmplexekjelenlétében vagy anélkül, LT-a/ aktiváló szerekként működnek. Anevezett LT-a/ heterőmer kőmplexek és/vagy anti- LT--R antitestekterápiásan hatásős mennyiségei gyógyszerkészítményekben neőplázia(daganatképződés) kezelésére alkalmazhatók. ŕ
HU9801746A 1995-01-26 1996-01-26 Lymphotoxin-alfa/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents HUP9801746A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26

Publications (2)

Publication Number Publication Date
HUP9801746A2 true HUP9801746A2 (hu) 1998-11-30
HUP9801746A3 HUP9801746A3 (en) 2000-11-28

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801746A HUP9801746A3 (en) 1995-01-26 1996-01-26 Lymphotoxin-alfa/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents

Country Status (25)

Country Link
EP (2) EP1407781A1 (hu)
JP (2) JPH10513161A (hu)
KR (2) KR100475492B1 (hu)
CN (3) CN1900116A (hu)
AT (1) ATE268604T1 (hu)
AU (1) AU725351B2 (hu)
BG (1) BG62599B1 (hu)
BR (1) BR9606808A (hu)
CA (1) CA2211443A1 (hu)
CZ (1) CZ298711B6 (hu)
DE (1) DE69632681T2 (hu)
DK (1) DK0809510T3 (hu)
EA (1) EA000096B1 (hu)
EE (1) EE04453B1 (hu)
ES (1) ES2220972T3 (hu)
FI (1) FI119359B (hu)
HK (1) HK1006356A1 (hu)
HU (1) HUP9801746A3 (hu)
NO (1) NO322744B1 (hu)
NZ (1) NZ303405A (hu)
PL (1) PL185364B1 (hu)
PT (1) PT809510E (hu)
RO (1) RO118634B1 (hu)
SK (1) SK286497B6 (hu)
WO (1) WO1996022788A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DK1119370T3 (da) 1998-10-09 2006-10-02 Biogen Idec Inc Omstödelse af virus-fremkaldt systemisk chok og respiratorisk besvær med blokering af lymfotoksin-beta-signalvejen
GEP20063752B (en) 2000-10-13 2006-02-27 Biogen Inc Humanized Anti-LT-Beta-R Antibodies
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2666934A1 (en) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
CA2737379A1 (en) * 2008-09-30 2010-04-08 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
AU2012348017A1 (en) * 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF
EP0536299B1 (en) * 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin

Also Published As

Publication number Publication date
FI119359B (fi) 2008-10-31
AU4970496A (en) 1996-08-14
DK0809510T3 (da) 2004-10-04
KR20040102364A (ko) 2004-12-04
EA000096B1 (ru) 1998-08-27
PL185364B1 (pl) 2003-04-30
NO973385D0 (no) 1997-07-22
CN1177302A (zh) 1998-03-25
JP2007169296A (ja) 2007-07-05
EE9700255A (et) 1998-04-15
KR100470739B1 (ko) 2005-09-02
BR9606808A (pt) 1997-12-30
CA2211443A1 (en) 1996-08-01
PL321758A1 (en) 1997-12-22
CZ298711B6 (cs) 2008-01-02
ES2220972T3 (es) 2004-12-16
CN1589902A (zh) 2005-03-09
DE69632681D1 (de) 2004-07-15
FI973118A0 (fi) 1997-07-25
ATE268604T1 (de) 2004-06-15
PT809510E (pt) 2004-09-30
KR100475492B1 (ko) 2005-03-14
EE04453B1 (et) 2005-04-15
RO118634B1 (ro) 2003-08-29
NO322744B1 (no) 2006-12-04
NO973385L (no) 1997-09-25
DE69632681T2 (de) 2005-06-09
CN1146442C (zh) 2004-04-21
EP0809510A1 (en) 1997-12-03
BG101855A (en) 1998-04-30
SK98697A3 (en) 2000-02-14
EP1407781A1 (en) 2004-04-14
BG62599B1 (bg) 2000-03-31
EP0809510B1 (en) 2004-06-09
HUP9801746A3 (en) 2000-11-28
EA199700144A1 (ru) 1997-12-30
SK286497B6 (sk) 2008-11-06
FI973118A (fi) 1997-09-25
CN1900116A (zh) 2007-01-24
AU725351B2 (en) 2000-10-12
HK1006356A1 (en) 1999-02-26
WO1996022788A1 (en) 1996-08-01
JPH10513161A (ja) 1998-12-15
MX9705629A (es) 1997-10-31
NZ303405A (en) 2000-02-28
CZ236197A3 (cs) 1998-02-18
KR19980701816A (ko) 1998-06-25

Similar Documents

Publication Publication Date Title
HUP9801746A2 (hu) Limfotoxin-alfa/béta komplexek és anti-limfotoxin-béta receptor antitestek mint tumorellenes szerek
NO931635L (no) Fremgangsmaate for fremstilling av kinazolin-derivater
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
WO2001066098A3 (en) Therapeutic uses of ppar mediators
AU7331094A (en) A3 adenosine receptor agonists
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
PL331709A1 (en) Cytotoxic aminosaccharic and affinite saccharic derivatives of indolopyrrole carbazoles
TR200000015T2 (tr) Bileşikler ve metodlar
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
NZ308789A (en) Tetralin derivatives and medicaments
UA41355C2 (uk) Засіб для лікування нейро-сніду
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
NZ326436A (en) Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
HUP0101947A2 (hu) Tumorok kezelésére szolgáló kombinációs készítmény
NO20020914D0 (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
DK0934342T3 (da) Præparat indeholdende chitosan
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten
ES2170479T3 (es) Agente viral terapeutico que detiene el desarrollo de tumores.
NO20000554L (no) Produkt inneholdende minst en dobbelt trådet RNA i kombinasjon med minst et 6-benzyluracilderivat
MX9605355A (es) El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees